Literature DB >> 24029120

EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung.

Kevin S Scher1, Juan-Sebastian Saldivar, Michael Fishbein, Alberto Marchevsky, Karen L Reckamp.   

Abstract

This case report describes the rare occurrence of a T790M resistance mutation found in a central nervous system (CNS) parenchymal metastasis. A concomitant squamous histology transformation in a lung non-T790M-resistant metastasis is also described. The authors hypothesize that this CNS resistance and histology transformation may have resulted from intermittent use of erlotinib treatment. This case report emphasizes the complexities of using erlotinib in the induction setting.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24029120     DOI: 10.6004/jnccn.2013.0126

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  14 in total

1.  Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR Inhibition.

Authors:  Pavel A Levin; Melissa Mayer; Sharon Hoskin; Joseph Sailors; Dwight H Oliver; David E Gerber
Journal:  J Thorac Oncol       Date:  2015-09       Impact factor: 15.609

2.  Downregulation of EGFR in a metastatic brain lesion of EGFR-mutated non-small cell lung cancer using a tyrosine kinase inhibitor: A case report.

Authors:  Masatoshi Takagaki; Manabu Kinoshita; Kazumi Nishino; Masakazu Nakano; Hiroko Adachi; Morio Ueno; Masanori Kitamura; Yasunori Fujimoto; Kei Tashiro; Yasuhiko Tomita; Fumio Imamura; Toshiki Yoshimine
Journal:  Oncol Lett       Date:  2017-02-06       Impact factor: 2.967

Review 3.  Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors.

Authors:  Yi Shao; Dian-Sheng Zhong
Journal:  Int J Clin Oncol       Date:  2017-11-07       Impact factor: 3.402

4.  EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: clinical correlations and response to therapy.

Authors:  Seerat Poonia; Eamon M Berge; Dara L Aisner; Denise Damek; Robert C Doebele
Journal:  Clin Lung Cancer       Date:  2014-05-15       Impact factor: 4.785

5.  Histologic transformation of non-small-cell lung cancer in brain metastases.

Authors:  Meng Jiang; Xiaolong Zhu; Xiao Han; Haiyan Jing; Tao Han; Qiang Li; Xiao Ding
Journal:  Int J Clin Oncol       Date:  2018-11-16       Impact factor: 3.402

6.  Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.

Authors:  Kenichi Suda; Isao Murakami; Kazuko Sakai; Hiroshi Mizuuchi; Shigeki Shimizu; Katsuaki Sato; Kenji Tomizawa; Shuta Tomida; Yasushi Yatabe; Kazuto Nishio; Tetsuya Mitsudomi
Journal:  Sci Rep       Date:  2015-09-24       Impact factor: 4.379

Review 7.  Pathological transition as the arising mechanism for drug resistance in lung cancer.

Authors:  Yueqing Chen; Waiying Yvonne Tang; Xinyuan Tong; Hongbin Ji
Journal:  Cancer Commun (Lond)       Date:  2019-10-01

Review 8.  Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review.

Authors:  Emma-Anne Karlsen; Sam Kahler; Joan Tefay; Shannon R Joseph; Fiona Simpson
Journal:  Cells       Date:  2021-05-14       Impact factor: 6.600

9.  Histological Transformation to Large Cell Neuroendocrine Carcinoma from Lung Adenocarcinoma Harboring an EGFR Mutation: An Autopsy Case Report.

Authors:  Rika Moriya; Satoshi Hokari; Satoshi Shibata; Takeshi Koizumi; Takafumi Tetsuka; Kazuhiko Ito; Hideki Hashidate; Hiroki Tsukada
Journal:  Intern Med       Date:  2017-08-01       Impact factor: 1.271

10.  Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report.

Authors:  Rossella Bruno; Agnese Proietti; Greta Alì; Gianfranco Puppo; Alessandro Ribechini; Antonio Chella; Gabriella Fontanini
Journal:  Oncol Lett       Date:  2017-09-08       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.